{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:40:25Z","timestamp":1794955225865,"version":"4.9.1"},"reference-count":117,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The treatment landscape for hepatitis C virus (HCV) infection has transformed over the past few decades, evolving from the limited efficacy of interferon (IFN) monotherapy to the highly successful pan-genotypic direct-acting antivirals (DAAs) used today. Initially, alpha-interferon monotherapy, introduced in the 1990s, was the standard treatment, yet it provided low sustained virological response (SVR) rates and caused significant adverse effects, limiting its utility. The development of pegylated interferon (peg-IFN) improved the pharmacokinetic profile of IFN, allowing for less frequent dosing and modestly improved response rates. When combined with ribavirin, peg-IFN achieved higher SVR rates, especially in non-genotype 1 HCV infections, but the combination also brought additional side effects, such as anemia and depression. The advent of the first-generation DAAs, such as telaprevir and boceprevir, marked a significant milestone. Combined with peg-IFN and ribavirin, these protease inhibitors boosted response rates in patients with genotype 1 HCV. However, high rates of adverse effects and drug resistance remained challenges. Second-generation DAAs, like sofosbuvir and ledipasvir, introduced IFN-free regimens with improved safety profiles and efficacy. The most recent advances are pan-genotypic DAAs, including glecaprevir-pibrentasvir and sofosbuvir-velpatasvir, which offer high SVR rates across all genotypes, shorter treatment durations, and fewer side effects. Current pan-genotypic regimens represent a cornerstone in HCV therapy, providing an accessible and effective solution globally.<\/jats:p>","DOI":"10.3390\/v17020163","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T07:33:11Z","timestamp":1737703991000},"page":"163","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs)"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3716-7010","authenticated-orcid":false,"given":"Lorenza","family":"Di Marco","sequence":"first","affiliation":[{"name":"SIcilian Network for Therapy, Epidemiology and Screening In Hepatology (SINTESI), 90127 Palermo, Italy"},{"name":"Department of Oncology and Hematology, Azienda Ospedaliero-University Hospital of Mod, 41124 Modena, Italy"},{"name":"Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41100 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Cannova","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Ferrigno","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Landro","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Nonni","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia La","family":"Mantia","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Cartabellotta","sequence":"additional","affiliation":[{"name":"SIcilian Network for Therapy, Epidemiology and Screening In Hepatology (SINTESI), 90127 Palermo, Italy"},{"name":"Department of Medicine, Buccheri-La Ferla Hospital, 90123 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0287-1059","authenticated-orcid":false,"given":"Vincenza","family":"Calvaruso","sequence":"additional","affiliation":[{"name":"SIcilian Network for Therapy, Epidemiology and Screening In Hepatology (SINTESI), 90127 Palermo, Italy"},{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Di Marco","sequence":"additional","affiliation":[{"name":"SIcilian Network for Therapy, Epidemiology and Screening In Hepatology (SINTESI), 90127 Palermo, Italy"},{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2017). Global Hepatitis Report 2017, World Health Organization."},{"key":"ref_2","unstructured":"Polaris Observatory HCV Collaborators (2022). Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: A modelling study. Lancet Gastroenterol. Hepatol., 7, 396\u2013415."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJM199212313272702","article-title":"The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team","volume":"327","author":"Alter","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.3748\/wjg.v13.i17.2436","article-title":"Epidemiology of hepatitis C virus infection","volume":"13","author":"Alter","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1053\/j.gastro.2018.10.033","article-title":"What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?","volume":"156","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-142-2-200501180-00009","article-title":"Antiviral therapy for cirrhotic hepatitis C: Association with reduced hepatocellular carcinoma development and improved survival","volume":"142","author":"Shiratori","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/cid\/civ197","article-title":"Hepatitis C virus therapeutic development: In pursuit of \u201cperfectovir\u201d","volume":"60","author":"Dore","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"ciad319","DOI":"10.1093\/cid\/ciad319","article-title":"Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"2023","author":"Bhattacharya","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2020). EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol., 73, 1170\u20131218.","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJM198612183152503","article-title":"Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report","volume":"315","author":"Hoofnagle","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/CMR.14.4.778-809.2001","article-title":"Antiviral actions of interferons","volume":"14","author":"Samuel","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM198911303212204","article-title":"Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial","volume":"321","author":"Martin","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJM198911303212203","article-title":"Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial","volume":"321","author":"Davis","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/0168-8278(90)90168-Q","article-title":"Recombinant alpha-interferon treatment of non-A, and non-B (type C) hepatitis: Review of studies and recommendations for treatment","volume":"11","author":"Davis","year":"1990","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"112S","DOI":"10.1002\/hep.510260720","article-title":"Side effects of alpha interferon in chronic hepatitis C","volume":"26","author":"Dusheiko","year":"1997","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1128\/JVI.72.4.2795-2805.1998","article-title":"Interferon resistance of hepatitis C virus genotype 1b: Relationship to nonstructural 5A gene quasispecies mutations","volume":"72","author":"Pawlotsky","year":"1998","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2893.2003.00457.x","article-title":"Dynamics of hepatitis C virus quasispecies turnover during interferon-alpha treatment","volume":"10","author":"Lee","year":"2003","journal-title":"J. Viral Hepat."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1023\/A:1010623417345","article-title":"Selection of HCV NS5Aquasispecies during IFN therapy in patients with chronic HCV","volume":"46","author":"Paterson","year":"2001","journal-title":"Dig. Dis. Sci."},{"key":"ref_20","first-page":"2201","article-title":"Peginterferon alfa-2a (40 kDa) monotherapy: A novel agent for chronic hepatitis C therapy","volume":"10","author":"Zeuzem","year":"2000","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-2003-41631","article-title":"Pharmacokinetics of peginterferons","volume":"23","author":"Zeuzem","year":"2003","journal-title":"Semin. Liver Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1046\/j.1365-2036.2003.01747.x","article-title":"Systematic review: Peginterferon vs. standard interferon in the treatment of chronic hepatitis C","volume":"18","author":"Zaman","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/j.1572-0241.2004.30306.x","article-title":"Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: A multicenter, randomized controlled trial","volume":"99","author":"Pockros","year":"2004","journal-title":"Am. J. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S1542-3565(04)00723-2","article-title":"Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection","volume":"3","author":"Lurie","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1111\/j.1572-0241.2007.01538.x","article-title":"Improving outcome in patients with hepatitis C virus genotype 4","volume":"102","author":"Kamal","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ajg.2013.427","article-title":"Host and viral determinants of the outcome of exposure to HCV infection genotype 4: A large longitudinal study","volume":"109","author":"Kamal","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3748\/wjg.v16.i12.1506","article-title":"Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C","volume":"16","author":"Yada","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jhep.2010.07.032","article-title":"Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b","volume":"54","author":"Kawaoka","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1099\/vir.0.029124-0","article-title":"IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations","volume":"92","author":"Ochi","year":"2011","journal-title":"J. Gen. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1089-3261(02)00077-6","article-title":"Current therapy for hepatitis C: Pegylated interferon and ribavirin","volume":"7","author":"McHutchison","year":"2003","journal-title":"Clin. Liver Dis."},{"key":"ref_31","first-page":"218","article-title":"Mechanism of action of ribavirin in the treatment of chronic hepatitis C","volume":"3","author":"Te","year":"2007","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","article-title":"Mechanism of action of interferon and ribavirin in treatment of hepatitis C","volume":"436","author":"Feld","year":"2005","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/jhep.2001.26371","article-title":"A randomized double- blind trial comparing pegylated interferon alfa-2b to inter-feron alfa-2b as initial treatment for chronic hepatitis C","volume":"34","author":"Lindsay","year":"2001","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","article-title":"Peginterferon alfa- 2a in patients with chronic hepatitis C","volume":"343","author":"Zeuzem","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJM200012073432302","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis","volume":"343","author":"Heathcote","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1002\/hep.21917","article-title":"Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response","volume":"46","author":"Kamal","year":"2007","journal-title":"Hepatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.mcg.0000145494.76305.11","article-title":"Hematologic side effects of interferon and ribavirin therapy","volume":"39","author":"Kowdley","year":"2005","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00535-012-0631-y","article-title":"Meta-analysis:mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C","volume":"48","author":"Minami","year":"2013","journal-title":"J. Gastroenterol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.4088\/JCP.12r07694","article-title":"Interferon-induced depression in chronic hepatitis C: A systematic review and meta-analysis","volume":"73","author":"Udina","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.2146\/ajhp110500","article-title":"Boceprevir: A recently approved protease inhibitor for hepatitis C virus infection","volume":"69","author":"Lam","year":"2012","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1586\/eri.11.133","article-title":"Telaprevir for the treatment of chronic hepatitis C infection","volume":"9","author":"Muir","year":"2011","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/PHAR.1046","article-title":"Boceprevir: A novel NS3\/4 protease inhibitor for the treatment of hepatitis C","volume":"32","author":"Klibanov","year":"2012","journal-title":"Pharmacotherapy"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1345\/aph.1P430","article-title":"Telaprevir: An NS3\/4A protease inhibitor for the treatment of chronic hepatitis C","volume":"45","author":"Smith","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2893.2012.01590.x","article-title":"A practical guide for the use of boceprevir telaprevir for the treatment of hepatitis C","volume":"19","author":"Jacobson","year":"2012","journal-title":"J. Viral Hepat."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"Forestier","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchison","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","article-title":"Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial","volume":"376","author":"Kwo","year":"2010","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1478-3231.2011.02707.x","article-title":"Boceprevir and telaprevir for the treatment of chronic hepatitis C: Safety management in clinical practice","volume":"32","year":"2012","journal-title":"Liver Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/1203475415595775","article-title":"Cutaneous Adverse Events in Chronic Hepatitis C Patients Treated with New Direct-Acting Antivirals: A Systematic Review and Meta-Analysis","volume":"20","author":"Patel","year":"2016","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep.26602","article-title":"Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir","volume":"59","author":"Mauss","year":"2014","journal-title":"Hepatology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1016\/j.dld.2013.07.008","article-title":"The importance of drug-drug interactions in the DAA era","volume":"45","author":"Back","year":"2013","journal-title":"Dig. Liver Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00228-014-1679-9","article-title":"Drug interactions and protease inhibitors used in the treatment of hepatitis C: How to manage?","volume":"70","author":"Lamblin","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2012.10.027","article-title":"Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions","volume":"58","author":"Burger","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrgastro.2013.106","article-title":"Drug-drug interactions during antiviral therapy for chronic hepatitis C","volume":"10","author":"Kiser","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","article-title":"New hepatitis C therapies: The toolbox, strategies, and challenges","volume":"146","author":"Pawlotsky","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"g3308","DOI":"10.1136\/bmj.g3308","article-title":"Antiviral treatment of hepatitis C","volume":"348","author":"Feeney","year":"2014","journal-title":"BMJ"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/cid\/ciu265","article-title":"Sofosbuvir in the treatment of chronic hepatitis C: New dog, new tricks","volume":"59","author":"Abraham","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1055\/s-0034-1371009","article-title":"Interferon-free strategies with a nucleoside\/nucleotide analogue","volume":"34","author":"Feld","year":"2014","journal-title":"Semin. Liver Dis."},{"key":"ref_70","first-page":"2367","article-title":"Changing the face of hepatitis C management\u2014The design and development of sofosbuvir","volume":"9","author":"Noell","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/jvh.12422","article-title":"Interferon-free, direct-acting antiviral therapy for chronic hepatitis C","volume":"22","author":"Gutierrez","year":"2015","journal-title":"J. Viral Hepat."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-015-0381-2","article-title":"Ledipasvir\/Sofosbuvir: A review of its use in chronic hepatitis C","volume":"75","author":"Keating","year":"2015","journal-title":"Drugs"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/apt.14478","article-title":"Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor","volume":"47","author":"Fourati","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.jhep.2015.08.010","article-title":"Management of direct-acting antiviral agent failures","volume":"63","author":"Buti","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/17425255.2017.1255725","article-title":"Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C","volume":"13","author":"Rivero","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/hepr.12673","article-title":"Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir\/asunaprevir therapy by a two-hit mechanism","volume":"46","author":"Uchida","year":"2016","journal-title":"Hepatol. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/apt.14977","article-title":"Review article: Novel antivirals for hepatitis C-sofosbuvir\/velpatasvir\/voxilaprevir, glecaprevir\/pibrentasvir","volume":"48","author":"Pearlman","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/nyas.12832","article-title":"Development of sofosbuvir for the treatment of hepatitis C virus infection","volume":"1358","author":"Lawitz","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1002\/hep.27161","article-title":"Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens","volume":"59","author":"Younossi","year":"2014","journal-title":"Hepatology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2014.09.023","article-title":"Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: An open-label study","volume":"148","author":"Curry","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/ajt.12714","article-title":"Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: \u201cA flood of opportunity\u201d","volume":"14","author":"Gane","year":"2014","journal-title":"Am. J. Transplant."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2014.10.001","article-title":"Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation","volume":"148","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial","volume":"383","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1001\/jama.2015.3860","article-title":"Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patientswith HCV genotype 1 infection","volume":"313","author":"Poordad","year":"2015","journal-title":"JAMA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1001\/jama.2015.3868","article-title":"Daclatasvir in combination with asunaprevir and beclabuvirfor hepatitis C virus genotype 1 infection with compensated cirrhosis","volume":"313","author":"Muir","year":"2015","journal-title":"JAMA"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1501315","article-title":"Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1","volume":"373","author":"Naggie","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.transproceed.2017.04.014","article-title":"Ledipasvir + Sofosbuvir for Liver Transplant Recipients with Recurrent Hepatitis C: A Systematic Review and Meta-Analysis","volume":"49","author":"Liao","year":"2017","journal-title":"Transplant. Proc."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.2147\/DDDT.S172512","article-title":"Glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C: Design, development, and place in therapy","volume":"13","author":"Cotter","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/17474124.2018.1411802","article-title":"Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C","volume":"12","author":"Hubbard","year":"2018","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/17474124.2017.1326817","article-title":"Sofosbuvir and velpatasvir for the treatment of hepatitis C","volume":"11","author":"Jackson","year":"2017","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1060028016668897","article-title":"Sofosbuvir\/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C","volume":"51","author":"Chahine","year":"2017","journal-title":"Ann. Pharmacother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12072-016-9776-8","article-title":"Sofosbuvir\/velpatasvir: A pangenotypic drug to simplify HCV therapy","volume":"11","author":"Lee","year":"2017","journal-title":"Hepatol. Int."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/hepr.13828","article-title":"Sofosbuvir\/velpatasvir and glecaprevir\/pibrentasvir: How should we choose among these two latest and probably the last regimens?","volume":"52","author":"Toyoda","year":"2022","journal-title":"Hepatol. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection","volume":"373","author":"Feld","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection","volume":"373","author":"Foster","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): A single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_104","first-page":"2134","article-title":"Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection","volume":"37","author":"Gordon","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/jvh.13738","article-title":"Safety analysis of glecaprevir\/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohorts","volume":"29","author":"Feld","year":"2022","journal-title":"J. Viral Hepat."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1007\/s12325-021-01753-3","article-title":"Safety of Patients with Hepatitis C Virus Treated with Glecaprevir\/Pibrentasvir from Clinical Trials and Real-World Cohorts","volume":"38","author":"Forns","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/hepr.13810","article-title":"Sofosbuvir-velpatasvir in adults with hepatitis C virus infection and compensated cirrhosis in Japan","volume":"52","author":"Takehara","year":"2022","journal-title":"Hepatol. Res."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Flamm, S., Lawitz, E., Borg, B., Charlton, M., Landis, C., Reddy, K.R., Shiffman, M., Alsina, A., Chang, C., and Ravendhran, N. (2023). Efficacy and Safety of Sofosbuvir\/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis. Viruses, 15.","DOI":"10.3390\/v15102026"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jhep.2019.06.002","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs","volume":"71","author":"Llaneras","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/apt.18020","article-title":"Real-life effectiveness of sofosbuvir\/velpatasvir\/voxilaprevir in hepatitis C patients previously treated with sofosbuvir\/velpatasvir or glecaprevir\/pibrentasvir","volume":"60","author":"Llaneras","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jhep.2024.04.007","article-title":"EASL position paper on clinical follow-up after HCV cure","volume":"81","author":"Reiberger","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/liv.15841","article-title":"Hepatitis C virus reinfection incidence among gay and bisexual men with HIV in Australia from 2016 to 2020","volume":"44","author":"Harney","year":"2024","journal-title":"Liver Int."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"103981","DOI":"10.1016\/j.drugpo.2023.103981","article-title":"The rate of hepatitis C reinfection in Canadians coinfected with HIV and its implications for national elimination","volume":"114","author":"Young","year":"2023","journal-title":"Int. J. Drug Policy"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"208937","DOI":"10.1016\/j.josat.2022.208937","article-title":"The experience of re-infection among people who inject drugs successfully treated for hepatitis C","volume":"146","author":"Karasz","year":"2023","journal-title":"J. Subst. Use Addict. Treat."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","article-title":"Global reporting of progress towards elimination of hepatitis B and hepatitis C","volume":"8","author":"Cui","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"13596535221083179","DOI":"10.1177\/13596535221083179","article-title":"Polaris Observatory-supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis","volume":"27","author":"Razavi","year":"2022","journal-title":"Antivir. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1056\/NEJMp2409842","article-title":"Leveraging Old Hepatitis C Therapies","volume":"392","author":"Tu","year":"2025","journal-title":"N. Engl. J. Med."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/2\/163\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:35:29Z","timestamp":1759919729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/2\/163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":117,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["v17020163"],"URL":"https:\/\/doi.org\/10.3390\/v17020163","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]}}}